The progressive deposition of insoluble amyloid protein plaques in specific areas of the brain and its blood vessels is associated with a number of neuropathologies and is an early invariant feature of Alzheimer’s disease. The major component of these protein plaques is a peptide of 39–42 amino acids derived from a group of 695–770 amino acid precursor proteins collectively referred to as the b-amyloid precursor protein (Beta-APP). b-APP is highly conserved in vertebrates; however, its normal function has not been well defined. In each of the b-APPs, the b-Amyloid peptide (b-AP) is an internal peptide that begins about 99 residues from the carboxy-terminal end of the b-APP and extends from the extracellular domain into the middle of the hydrophobic, membrane spanning domain of the precursor protein. The precise mechanism whereby b-AP accumulates in brain remains poorly defined.

Suitable for use in FLISA, Immunohistochemistry and Western Blot. Other applications not tested.

Immunohistochemistry (alcohol-fixed, parrafin embedded, frozen): ~10ug/ml It is nessessary to pretreat the tissue with trypsin digestion. Western Blot: 0.1-0.2ug/ml FLISA: 0.5-1.0ug/ml Optimal dilutions to be determined by the researcher.

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap. 

Note: Applications are based on unconjugated antibody.